Maria Gerosa1, Pier Luigi Meroni, Doruk Erkan. 1. aDepartment of Clinical Sciences and Community Health, Division of Rheumatology, Ospedale Gaetano Pini, University of Milan bLaboratory of Immuno-rheumatology, Istituto Auxologico Italiano, Milan, Italy cBarbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, USA.
Abstract
PURPOSE OF REVIEW: This article summarizes the recent developments in the recognition and management of antiphospholipid syndrome (APS). RECENT FINDINGS: Five Task Forces, created as part of the 14th International Congress on antiphospholipid antibodies (aPL), published their systematic reviews. 'For the recognition of APS': the assessment of aPL profile is crucial for risk stratification; lupus anticoagulant positivity, especially in the context of 'triple aPL positivity' displays the highest risk; a panel of criteria and noncriteria aPL tests may help better risk-stratify the aPL-positive in the future. 'For the management of APS': direct oral anticoagulants are not currently recommended; statins ameliorate the proinflammator/thrombotic markers, whereas hydroxychloroquine reduces the risk of thrombosis in experimental models and lupus patients, which justify their use as an adjunctive treatment in refractory cases; B-cell inhibition may have a role in difficult-to-treat patients with hematologic and microthrombotic/angiopathic manifestations; and complement and mammalian targets of rapamycin complex pathway inhibition are promising targets in APS. SUMMARY: Warfarin, heparin, and/or antiplatelet drugs are the standard of care for aPL-positive patients. Recent studies suggest novel approaches that target new coagulation and immunomodulatory pathways; mechanistic and/or controlled clinical studies are needed to determine the effectiveness of these novel approaches.
PURPOSE OF REVIEW: This article summarizes the recent developments in the recognition and management of antiphospholipid syndrome (APS). RECENT FINDINGS: Five Task Forces, created as part of the 14th International Congress on antiphospholipid antibodies (aPL), published their systematic reviews. 'For the recognition of APS': the assessment of aPL profile is crucial for risk stratification; lupus anticoagulant positivity, especially in the context of 'triple aPL positivity' displays the highest risk; a panel of criteria and noncriteria aPL tests may help better risk-stratify the aPL-positive in the future. 'For the management of APS': direct oral anticoagulants are not currently recommended; statins ameliorate the proinflammator/thrombotic markers, whereas hydroxychloroquine reduces the risk of thrombosis in experimental models and lupuspatients, which justify their use as an adjunctive treatment in refractory cases; B-cell inhibition may have a role in difficult-to-treat patients with hematologic and microthrombotic/angiopathic manifestations; and complement and mammalian targets of rapamycin complex pathway inhibition are promising targets in APS. SUMMARY:Warfarin, heparin, and/or antiplatelet drugs are the standard of care for aPL-positive patients. Recent studies suggest novel approaches that target new coagulation and immunomodulatory pathways; mechanistic and/or controlled clinical studies are needed to determine the effectiveness of these novel approaches.
Authors: Paolo Durigutto; Claudia Grossi; Maria Orietta Borghi; Paolo Macor; Francesca Pregnolato; Elena Raschi; Michael P Myers; Philip G de Groot; Pier Luigi Meroni; Francesco Tedesco Journal: Haematologica Date: 2018-11-15 Impact factor: 9.941
Authors: Jae Won Kim; Tae Woo Kim; Keon Hee Ryu; Sun Gyoo Park; Chang Young Jeong; Dong Ho Park Journal: J Int Med Res Date: 2020-01 Impact factor: 1.671
Authors: Carlos Tortosa; Oscar Cabrera-Marante; Manuel Serrano; José A Martínez-Flores; Dolores Pérez; David Lora; Luis Morillas; Estela Paz-Artal; José M Morales; Daniel Pleguezuelo; Antonio Serrano Journal: PLoS One Date: 2017-07-20 Impact factor: 3.240